Amgen is an expert in biologics manufacturing. We have been at the forefront of the medical biotechnology revolution that started in the 1980s, helping invent the processes, methods and technologies that built the global biotechnology industry. In Europe our first manufacturing facility was established in Breda, the Netherlands in 1996.
Amgen has an outstanding track record of reliably delivering medicines to patients who need them. Our highly skilled workforce, disciplined approach to operational excellence and risk mitigation efforts contribute to our commitment to ensure supply for “every patient, every time.” Our Amgen manufacturing facilities in Europe deliver biologic medicines to patients all around the world.
Amgen Breda (ABR) was established in 1996 and commissioned in 1997. It is a multifunctional site hosting several organizations with approximately 660 employees on site: Site Operations, Global Supply Chain Europe and TMEA, Clinical Operations, International Operations IS and IS Site, the Netherlands Affiliate, Financial Services and Global Business Services.
The site is located on 5.4 hectares (13.34 acres) and is designed around 3 areas - offices, production hall and warehouse.
Our production facility assembles, labels and pack around 25 million units annually. Fully automated for large production orders, semi-automated and manual for smaller production orders, all according country specific requirements. Our distribution center receives and checks all incoming components and ensures that products will be ready for final shipment around the globe, carefully checked for quality before releasing to the market.
Purchased by Amgen in May 2011, Amgen Dún Laoghaire (ADL) is a 37,000 square meter aseptic operations facility, specializing in secondary manufacturing activities (both vial and syringe)– formulation, fill, Lyophilization and packaging. It hosts over 430 employees specialized in these operations.
The ADL site also includes laboratories and cold chain warehouse capabilities.
Our ADL site has multiple roles within Amgen:
The site has the stainless steel capacity to produce global demand for liquid products. ADL has the capability to produce over 90% of Amgen's medicines, helping to ensure continuity of supply as we expand internationally
The site has the headcount capacity to operate one filling suite at a time either vial filling or syringe filling.